Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study

Table 2 Number of small-bowel mucosal injuries and CE scores upon initial and follow-up CE in the polaprezinc treatment group and non-polaprezinc (control) group

	Initial CE	Follow-up CE	Pvalue
Polaprezinc group (n = 10)
Median number of erosions/ulcers (range)	2 (0-6)	0 (0-4)	0.039*
Median number of reddened lesions (range)	3 (0-7)	1 (0-1)	0.003*
Median CE score (range)	180 (0-450)	0 (0-225)	N.S.*
CE score by category
Normal or clinical insignificant change (<135)	3	6
Mild change (≥135 and <790)	7	4	N.S.**
Moderate or severe change (≥790)	0	0
Control group (n = 10)
Median number of erosions/ulcers (range)	2 (0-10)	0 (0-9)	N.S.*
Median number of reddened lesions (range)	2 (0-7)	2 (0-7)	N.S.*
Median CE score (range)	225 (0-225)	0 (0-450)	N.S.*
CE score by category
Normal or clinically insignificant change (<135)	4	6
Mild change (≥135 and <790)	6	4	N.S.**
Moderate or severe change ((≥790)	0	0

ISSN: 1471-230X